A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

• Drug: PF-06427878
  
  PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
• Drug: Placebo
  
  PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

• Experimental: Cohort 1-PF-06427878 or placebo
  
  Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
  Interventions:
  

  • Drug: PF-06427878
  • Drug: Placebo
• Experimental: Cohort 2-PF-06427878 or placebo
  
  Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
  Interventions:
  

  • Drug: PF-06427878
  • Drug: Placebo
• Experimental: Cohort 3-PF-06427878 or placebo
  
  Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
  Interventions:
  

  • Drug: PF-06427878
  • Drug: Placebo

Inclusion Criteria:

• Healthy male and/or female subjects of non childbearing potential.
• Body Mass Index (BMI) of 17.5 to 35.4 kg/m2; and a total body weight >50 kg
• Subjects with fasting TG level of >=90 mg/dL and <=500 mg/dL following an overnight fast

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).